FDA refuses sNDA for Allergan's Vraylar

Allergan plc (NYSE:AGN) said FDA issued a refusal to file letter to an sNDA for Vraylar cariprazine (MP-214, RGH-188) to treat negative symptoms associated with schizophrenia in adults. According to Allergan, the agency said the application was not complete...